Business
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics,
About this update from Bolt Biotherapeutics, Inc.
[{"type":"text","content":"Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials\nREDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today announced that it will present a poster with clinical data from its completed Phase 1 dose-escalation study of BDC-1001 at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting. The conference is being held at McCormick Place in Chicago, Illinois and virtually from June 2-6, 2023. BDC-1001 is an investigational Immune-Stimulating Antibody Conjugate (ISAC) in development for the treatment of patients with HER2-expressing cancer. The ASCO presentation will include comprehensive results from the company’s Phase 1 single-agent and combination dose-escalation trial of BDC-1001 that enrolled more than 100 patients. “We look forward to presenting a comprehensive data set at ASCO that provides detailed safety, efficacy, pharmacokinetic and pharmacodynamic results from our recently completed Phase 1 dose-escalation trial evaluating BDC-1001 as a single agent and in combination with nivolumab,” said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. “These data support the recommended Phase 2 dose and schedule for BDC-1001. We are making steady progress towards initiating two Phase 2 studies in 2023 evaluating BDC-1001 in multiple single-agent solid tumor settings, and in combination with nivolumab supplied by our partner BMS and with pertuzumab supplied by our partner Roche.” Details about the presentation can be found below and on the ASCO website. Additionally, a copy of the poster will be available on the Publications page of the Bolt Biotherapeutics website following the conference. Title: A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumorsPresenter: Bob Li, M.D., Ph.D., MPH, medical oncologist, and principal investigator at Memorial Sloan Kettering Cancer Center (MSK)Abstract Presentation Number: 2538Poster Session: Developmental Therapeutics—ImmunotherapyDetails: Saturday, June 3, 2023, 8:00 a.m. - 11:00 a.m. CDT About BDC-1001 Bolt Biotherapeutics’ lead program, BDC-1001, is a human epidermal growth factor re...